Healthcare industry
Research Topic
Language: English
This is a research topic created to provide authors with a place to attach new problem publications.
Research topics above this in the hierarchy
Research problems linked to this topic
- Detailed company data on sales to the NHS.
- Detailed data on the dates of regulatory approval and cost-effectiveness appraisal of medicines and medical technologies.
- Detailed data on uptake and access of medicines and medical technologies at the level of each commissioning unit.
- Are there health and safety challenges associated with growing industries including the retrofitting of domestic and commercial buildings; installation of low carbon heat solutions & installation of electrical infrastructure for electric vehicles?
- Manufacturing Innovation: We would like to have a more comprehensive forward look for new drugs, devices, or other therapeutics to identify potential innovations faster.
- The risk of an unknown pandemic human disease (“disease x) has been at the top of the National Risk Register for some time and been realised this year in the shape of COVID-19. Two thirds of new human infectious diseases originate in animals. How can we better understand and prepare for future threats? How can we better join up animal and human health research, capability, and digital backbone across government to facilitate agile responses?
- Evidence on inequality of access to and benefit from treatments.
- Detailed data on the price per QALY associated with each medicine and medical technology purchased by the NHS.
- We would like to understand how clinical trial activity is affected by the broader commercial environment and, in particular, price regulation and other cost control measures.
- What is the UK’s long-term requirement for natural resources from global markets? Which resources are exposed to production/supply risks owing to geopolitical, macro-economic, pandemic, or environment factors and what are the likely impacts of change to the UK economy?
- What impact will the copper switch off have on the resilience for networks and their usage? How might it impact public sector service providers, such as care homes, emergency services and other NHS sites? How aware are customers that the copper switch off is taking place and what risks come from this for the market?
- Estimates of the returns to R&D spending in these disease areas.
- What are the most effective ways to engage employers, health professionals, employees and other relevant stakeholders to retain and support disabled people and people with health conditions in employment? What policies and processes do employers have in place that could influence employee health, well-being and productivity (such as sick pay, access to occupational health services, health insurance provision)?
- Estimates of the benefit and impact of introducing new technologies and therapeutics to the NHS.
- Estimates of the potential market size for AI-related services in the life sciences sector.
- What is the burden of antimicrobial resistance (AMR) in the environment and within food systems, and to what extent is this facilitating the development and transmission of AMR between animal and human populations?
- Detailed data on companies that specialise in the provision of AI services in life sciences.
- The role that all parts of the health system, from community and primary care through to hospital-based and social care, play in delivering better outcomes for people, and how the system can work effectively together to plan for and respond to compound pressures including infections with pandemic potential.
- How can we better understand and prevent the development of antimicrobial and anthelmintic resistance? How can we develop better diagnostic tests to encourage more judicious use of antimicrobials and anthelmintics?